CAKs integrates several clinical trial sites in Taiwan, providing standardized clinical trial protocol, ensuring clinical trial quality and adherence. CAKs have credibility to provide trustworthy clinical trial data and promote the international clinical trial for kidney disease in Taiwan.

CAKs is dedicated to

1.Share the clinical data and research result..

2.Promote clinical related research for new medication, medical equipment, and medical technique for kidney disease in Taiwan.

Academic achievements︰

• CAKs Consultant Chiu-Ching Huang’s research team has developed detection assay for urothelial carcinoma with serum and urine miRNA. Such result had won the honor of the National Innovation Award in 2021 and the silver award in Taiwan Innovation Technology Expo in October, 2021.
• CAKsConsultants Chiu-Ching Huang of the China Medical University Hospital and VinCent Wu of National Taiwan University Hospital. were also selected as the World’s top 2％ influential lifetime scientists during 1960-2020 by Stanford University.
• CAKs members actively strive to publish relevant research papers

 

Technical achievements︰

We are currently developing artificial intelligence model (Intelligent Kidney Disease Progression Prediction, KDPP) to predict the course of kidney disease. This model is aimed to identify potential disease progression or complication of acute kidney injury from clinical characteristics/risk factors and the development of this model was relied on the help from the CAKs platform and the domestic manufacturer EVERFORTUNE, AI incorporation. The goal off KDPP is to screen for patients at high risk of renal function deterioration. It also provides risk warning to medical care personnel. Through early clinical intervention, the risk of renal failure in patients with chronic kidney disease can be reduced or delayed, which will greatly improve the health of patients and achieve sustainable health insurance.  

Economic benefits：

1. Through the "Multidisciplinary post-acute kidney injury study ", we would acquire first-handed real-world, prospective clinical data. The local Taiwan domestic pharmacy that producing therapeutic drug ACEi/ARB may be benefited from obtaining these valuable data. In the future, if possible, further collaboration would be conducted with domestic pharmacy. CAKs will keep attempt to bridge/initiate further clinical trials with domestic pharmacy. The result would also be applied for post-AKI to CKD care. 
2. CAKs can provide platform for exchange of clinical experience, academic research, and medical resources. Such platform could facilitate early diagnosis and prompt treatment for patients with kidney disease and reduce health care expenditures.

 

Social benefits︰

1. We will integrate AKD care with already existed “National Health Insurance Pre-End Stage Renal Disease (pre-ESRD) Patient Care and Education Program” with our study “Multidisciplinary post-acute kidney injury study ". Such collaboration would provide holistic care including education, nutritionist, pharmacist for individualized guidance. Through multi-faceted disease management, emphasizing the monitoring of changes in renal function and proteinuria, patients with acute kidney disease and their families can find their own healthy living style.
2. Currently, there is no routine health education after the subject during nephrology follow-up, which forms a care “gap” between AKI and CKD. Our goal is to fill such “gap” by making health education brochure and help patients for more detailed health information. Such education is crucial for preventing AKI to CKD progression.